Asset Allocation Outlook Q3 2026: Staying Pro-Risk In A Broadening AI Cycle

The AI buildout has evolved from a pure technology theme to driving a full macro cycle. We maintain an overweight to global ...

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...

Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...

Putnam Small Cap Growth Fund Q1 2026 Commentary

For the quarter, the fund (class Y) outperformed its benchmark, the Russell 2000 Growth Index. Read more here.